INDIA'S TORRENT PHARMA LAUNCHES SPECIALTY DIVISIONS

Indian drugmaker Torrent Pharma has launched three new specialty divisions: Omega, Sensa and Alfa. The new divisions will cater to the fast-growing niche therapeutic areas of cardiovascular health/diabetes, central nervous system (CNS) and gastrointestinal.

Omega, the new cardiovascular/diabetes division, will exclusively focus on the cardiovascular and metabolic diseases, with special focus on diabetes and nephrology. Omega will complement Torrent's existing cardiovascular/diabetes divisions, Azuca, Delta and Psycan, and will help the company increase its market share considerably, according to the company.

The new CNS division, Sensa, will focus exclusively on the ailments that affect the geriatric population. This includes Parkinson's disease, Alzheimer's disease and depression.

The third new division, Alfa, is in the mass products segment and will focus on gastrointestinal, orthopedics and anti-infectives. Alfa will join the existing divisions, Prima and Vista, in the gastrointestinal category. The company plans to deploy roughly 200 new field personnel in this new division to drive growth.

Torrent Pharma has long followed a segmentation strategy to improve its doctor coverage and generate incremental business through the prescription generation route.